Exploring Acne Treatments Through Clinical Research Participation
Advancing Acne Care - Clinical Trials Open for Patient Enrollment
1 other identifier
observational
500
1 country
1
Brief Summary
The purpose of this study is to understand the lived experiences of acne patients enrolled in a related clinical trial testing a particular treatment. The primary focus will be on tracking trial adherence and dropout rates to enhance future research and care approaches, especially for underserved groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2025
CompletedFirst Posted
Study publicly available on registry
June 8, 2025
CompletedStudy Start
First participant enrolled
June 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
Study Completion
Last participant's last visit for all outcomes
June 1, 2028
June 8, 2025
May 1, 2025
1 year
May 30, 2025
May 30, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Rate of patients who decide to enroll in an acne clinical research.
3 month
Number of acne study participants who remain in clinical study until completion.
12 months
Eligibility Criteria
Patients with acne who are actively considering enrolling in a clinical trial for said condition, but have not yet completed enrollment and randomization phases.
You may qualify if:
- Patients diagnosed with acne.
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.
You may not qualify if:
- Refusal of consent
- Women of childbearing potential without a negative pregnancy test; or women who are lactating.
- Any serious and/or unstable pre-existing medical disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Power Life Sciences
San Francisco, California, 94107, United States
Related Publications (3)
Eichenfield DZ, Sprague J, Eichenfield LF. Management of Acne Vulgaris: A Review. JAMA. 2021 Nov 23;326(20):2055-2067. doi: 10.1001/jama.2021.17633.
PMID: 34812859BACKGROUNDWilliams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29.
PMID: 21880356BACKGROUNDTitus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012 Oct 15;86(8):734-40.
PMID: 23062156BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Michael B Gill
Power Life Sciences Inc.
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2025
First Posted
June 8, 2025
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2028
Last Updated
June 8, 2025
Record last verified: 2025-05